开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

休市中 09-04 16:08:02

1.820

-0.075

-3.96%

最高2.000	最低1.820	成交量85.10万
今开2.000	昨收1.895	日振幅9.50%
总市值9.08亿	流通市值9.08亿	总股本4.99亿
成交额161.57万	换手率0.17%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":1.82,"timestamp":1788509282139,"preClose":1.895,"halted":0,"volume":851000,"delay":0,"changeRate":-0.039577836411609474,"floatShares":499000000,"shares":499000000,"eps":-0.5200652163726183,"marketStatus":"休市中","change":-0.075,"latestTime":"09-04 16:08:02","open":2,"high":2,"low":1.82,"amount":1615727,"amplitude":0.094987,"askPrice":1.89,"askSize":6500,"bidPrice":1.82,"bidSize":36500,"shortable":0,"etf":0,"ttmEps":-0.4696456379048067,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788744600000},"marketStatusCode":7,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":1.895,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":0.39024166553098294,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2664332059","title":"礼邦医药-B(09637)H股获纳入港股通及恒生综合指数","url":"https://stock-news.laohu8.com/highlight/detail?id=2664332059","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664332059?lang=zh_cn&edition=full","pubTime":"2026-09-04 21:34","pubTimestamp":1788528840,"startTime":"0","endTime":"0","summary":"H股获纳入港股通乃基于其获纳入恒生综合指数。根据恒生指数有限公司于2026 年8月21日公布的截至2026年6月30日的恒生指数系列季度检讨结果，H股获纳入恒生综合指数成份股，有关变动已于2026年9月4日(星期五)收市后实施，并将自 2026年9月7日(星期一)起生效。董事会认为，H股获纳入港股通及恒生综合指数，反映了资本市场对公司价值及长期发展前景的认可，并将有助于进一步扩大公司的投资者基础，提升H股的交易流动性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","FLHK","BK1191","09939","09637","BK1574","HSCI","BK1161","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664067330","title":"【千亿药企龙头深度拆解】序章：读懂医药龙头的定价底层逻辑","url":"https://stock-news.laohu8.com/highlight/detail?id=2664067330","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664067330?lang=zh_cn&edition=full","pubTime":"2026-09-04 16:35","pubTimestamp":1788510900,"startTime":"0","endTime":"0","summary":"理解这一底层逻辑，是有效开展港股医药投研的第一步。当前港股千亿药企格局呈现明显分化态势，不同类型企业的估值逻辑与涨跌驱动因素各不相同，这也为投资者提供了多样化的观察与配置视角。本专栏拆解的上市企业均为该榜单的核心候选，兼具行业代表性与市场影响力，亦是观察港股医药板块动态的重要参考坐标。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514105&idx=2&sn=d8ca392d4d324022cb2b4462bb9bc726&chksm=f304d4e6dbfa638c7d6757b3f5ceecdad7dcb1117ab48872a6f207ed5cbe7e1509d99613c06d&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1515","09939","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664369163","title":"纽欧申医药完成逾8000万美元的B轮超额融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2664369163","media":"经纬创投","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664369163?lang=zh_cn&edition=full","pubTime":"2026-09-04 12:19","pubTimestamp":1788495540,"startTime":"0","endTime":"0","summary":"综述近日，纽欧申医药宣布完成逾8000万美元的B轮超额融资，经纬创投参与投资。三大核心项目均处于临床阶段目前，纽欧申医药已构建起涵盖小分子创新药的差异化研发管线，三大核心项目均处于临床开发阶段：NS-079 · 非致幻性5-HT2A受体部分激动剂开拓难治性抑郁症新路径NS-079的核心作用机制是神经可塑性调节。目前，NS-079已在澳洲启动首次人体试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3ODk5OTEzOA==&mid=2962188653&idx=2&sn=9648168cc3abbfe551d228585ca0897a&chksm=abf451d91501b032eafed6bf17710a8b01a3f275a7235b49ed55199b530f45fcd590769d04a4&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["159938","BK1515","09939","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664388377","title":"劲方医药-B(02595)存仓市值总计19.55亿港元 股东将4373.09万股股票存入渣打银行(香港)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664388377","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664388377?lang=zh_cn&edition=full","pubTime":"2026-09-04 08:34","pubTimestamp":1788482051,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，9月3日，劲方医药-B(02595)出现存仓异动，存仓市值总计19.55亿港元，占比19.65%。该公司股东将4373.09万股股票存入渣打银行(香港)，持股比例增加12.44%。劲方医药此前发布公告，GFH375已进入一线治疗KRAS G12D突变型晚期非小细胞肺癌(NSCLC)的II期研究，包括单药疗法、联合EGFR单抗(西妥昔单抗)或联合化疗(培美曲塞)三种治疗方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","BK1515","02595","159938","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664879974","title":"劲方医药-B(02595)9月3日斥资54.64万港元回购2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664879974","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664879974?lang=zh_cn&edition=full","pubTime":"2026-09-03 19:21","pubTimestamp":1788434461,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月3日斥资54.64万港元回购2万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491703.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","159938","02595","BK1574","BK1515","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664824858","title":"港股异动 | 同源康医药-B(02410)午后涨超9% EGFR-TKI氘申艾替尼获批一线治疗晚期非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2664824858","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664824858?lang=zh_cn&edition=full","pubTime":"2026-09-03 14:30","pubTimestamp":1788417020,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B午后涨超9%。消息面上，同源康医药近日宣布，公司自主研发的新一代EGFR-TKI创新药甲磺酸氘申艾替尼片已正式获得中国国家药品监督管理局批准附条件上市，适应症为具有表皮生长因子受体外显子19缺失或外显子21置换突变，并伴有中枢神经系统转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。同源康预计收取7亿元人民币现金首付款及股份认购款，以及最高20.6亿元人民币的注册里程碑付款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","KCAI","VXUS","BK4588","09939","159938","BK1161","BK4585","02410","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664875595","title":"沃生医药完成 1500 万美元新一轮融资 |【经纬低调新闻】","url":"https://stock-news.laohu8.com/highlight/detail?id=2664875595","media":"经纬创投","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664875595?lang=zh_cn&edition=full","pubTime":"2026-09-03 11:52","pubTimestamp":1788407520,"startTime":"0","endTime":"0","summary":"综述聚焦中枢神经退行性疾病的平台型生物技术企业苏沃生医药，完成总额1500万美元新一轮融资。本轮融资由经纬创投领投。经纬观点作为领投方，经纬创投是沃生最大的外部机构股东之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3ODk5OTEzOA==&mid=2962188635&idx=2&sn=8af16f84410e03d3b16112f593d5b2f7&chksm=abb4a57eea7e930e64d4bf3ee886a2044bfba6ac7da17ac0d6273485f22df6fd7dbd6180cdb4&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1161","BK1515","BK1574","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664900840","title":"普莱医药冲刺港股：上半年净亏8524万 陈育新控制36%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2664900840","media":"雷递网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664900840?lang=zh_cn&edition=full","pubTime":"2026-09-03 09:09","pubTimestamp":1788397741,"startTime":"0","endTime":"0","summary":"普莱医药(江苏)股份有限公司（简称：“普莱医药”）日前更新招股书，准备在港交所上市。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260903/6392402332203885668434286.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260903/6392402332203885668434286.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n35053/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["09939","BK1161","BK4588","BK1574","BK4585","159938","VXUS","KCAI","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664517826","title":"倒计时5天｜科创出海，药启新程·2026上海国际医药健康创新与资本大会暨第15届医药CEO论坛","url":"https://stock-news.laohu8.com/highlight/detail?id=2664517826","media":"国泰君安证券研究","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664517826?lang=zh_cn&edition=full","pubTime":"2026-09-03 06:00","pubTimestamp":1788386400,"startTime":"0","endTime":"0","summary":"重要提醒本订阅号所载内容仅面向国泰海通证券研究服务签约客户。因本资料暂时无法设置访问限制，根据《证券期货投资者适当性管理办法》的要求，若您并非国泰海通证券研究服务签约客户，为保证服务质量、控制投资风险，还请取消关注，请勿订阅、接收或使用本订阅号中的任何信息。法律声明本公众订阅号为国泰海通证券股份有限公司 研究所依法设立、独立运营的唯一官方订阅号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MzEwMDEzNQ==&mid=2650541224&idx=1&sn=96b854d0fb78e4b940add5b94cc33930&chksm=89e6fb4c40a99915c57ffe22214f7bda91fc77d8e4f1bbad8d570060cbd46cc5946410d99e25&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1161","BK1515","159982","BK1574","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664845077","title":"股市必读：大参林新发布《大参林医药集团股份有限公司2026年第二次临时股东会会议材料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664845077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664845077?lang=zh_cn&edition=full","pubTime":"2026-09-03 02:34","pubTimestamp":1788374054,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，大参林报收于18.08元，下跌1.79%，换手率0.57%，成交量6.51万手，成交额1.19亿元。公司公告汇总大参林医药集团股份有限公司2026年第二次临时股东会会议材料大参林拟通过员工持股平台广州集芸智投资服务合伙企业间接参股安徽大参林药业有限公司和新疆大参林医药连锁有限公司。公司放弃相关优先权利，本次交易不影响合并报表范围及控制权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300002211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603233","BK0185","BK0114","159938","BK1515","09939","BK1574","BK0209","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664984574","title":"股市必读：福瑞达新发布《鲁商福瑞达医药股份有限公司关于控股股东协议转让部分公司股份过户完成的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664984574","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664984574?lang=zh_cn&edition=full","pubTime":"2026-09-03 02:24","pubTimestamp":1788373453,"startTime":"0","endTime":"0","summary":"公司公告汇总鲁商福瑞达医药股份有限公司关于控股股东协议转让部分公司股份过户完成的公告鲁商福瑞达医药股份有限公司控股股东山东省商业集团有限公司与山东省国有资产投资控股有限公司于2026年8月6日签署《股份转让协议》，拟转让公司50,828,500股股份，转让价格为5.384元/股，转让对价273,660,644.00元。转让后，山东省商业集团有限公司持股比例由51.62%降至46.62%，山东国投持股比例为5.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300002130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0273","159938","09939","600223","BK0188","BK1515","BK1161","BK0229","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664815269","title":"劲方医药-B(02595)9月2日斥资107.63万港元回购3.9万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815269","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664815269?lang=zh_cn&edition=full","pubTime":"2026-09-02 19:06","pubTimestamp":1788347190,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月2日，该公司斥资107.63万港元回购3.9万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","159938","09939","BK1515","02595"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664894762","title":"迪哲医药二度递表港交所：上半年亏损超2亿，“小众靶点”天花板与现金流双重压力并存","url":"https://stock-news.laohu8.com/highlight/detail?id=2664894762","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664894762?lang=zh_cn&edition=full","pubTime":"2026-09-02 15:46","pubTimestamp":1788335190,"startTime":"0","endTime":"0","summary":"目前，迪哲医药两款核心产品舒沃哲和高瑞哲均已进入国家医保目录。截至2026年中，迪哲医药无控股股东和实际控制人。就在9月1日，迪哲医药发布公告称，公司与阿斯利康签署《许可协议》，授予阿斯利康在全球范围内独家开发、商业化舒沃哲的权利。不过，市场依然对两款产品的天花板存在争议。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788335043232116627","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IPOS","BK1515","BK4588","159938","BK1574","BK4585","159399","SPHQ","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144703788","title":"港股开盘｜港股低开；医药股逆市走强；联想涨逾2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144703788","media":"港股开盘","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144703788?lang=zh_cn&edition=full","pubTime":"2026-09-02 09:23","pubTimestamp":1788312190,"startTime":"0","endTime":"0","summary":"核心科网股表现分化：受AI服务器需求利好刺激，联想集团逆势上涨逾2%，其余多数龙头回调0.2%–1%不等。盘面异动方面，数据中心概念新意网高开近7%领跑；医药股获资金青睐，先声药业、云顶新耀等延续强势；黄金股则受金价走弱影响集体下挫，万物云大跌近7%拖累物业管理板块。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","HK0000320223.HKD","LU0890818403.SGD","LU0310800965.SGD","LU0572939691.SGD","LU1366334578.USD","TCHI","VXUS","80992","09939","BK4585","IE0032431581.USD","LU0370786039.SGD","LU1046422090.SGD","BK1607","LU0128525689.USD","LU0029875118.USD","LU0128522157.USD","LU2242644610.SGD","BK1193","159938","BK1161","HK0000320264.USD","HK0000306685.HKD","LNVGY","LU0791591158.USD","BK1515","LU1366334651.USD","LU1267930227.SGD","BK4588","LU0791590937.USD","LU0972618739.USD","00992","IE00B0JY6N72.USD","LU0264606111.USD","IE0003895053.USD","LU0320764755.SGD","LU0862451753.SGD","LU0049112450.USD","LU0048580855.USD","LU0543330483.HKD","LU1785774172.SGD","IE0034224299.USD","KCAI","LU0052756011.USD","LU0572940350.SGD","LU0672654166.SGD","03441","BK1526","LU1235295612.USD","BK1574","LU0862451837.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165279835","title":"开拓药业-B2026年8月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1165279835","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165279835?lang=zh_cn&edition=full","pubTime":"2026-09-01 16:38","pubTimestamp":1788251912,"startTime":"0","endTime":"0","summary":"开拓药业有限公司于2026年9月1日发布截至2026年8月31日的证券变动月报表。报告显示，截至8月末，公司法定股本总额仍为70,000美元，普通股法定/注册数量保持在700,000,000股，面值为每股0.0001美元。公司确认其已满足上市规则要求的最低公众持股量标准。公司表示，所有证券发行及股份变动均已依据相关法规及香港联交所上市规则履行必要程序和获得正式批准。本次公告由公司主席、执行董事及行政总裁童友之签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664857039","title":"【生物医药小白投研】第六篇：小白也能上手的医药股估值与前景打分体系","url":"https://stock-news.laohu8.com/highlight/detail?id=2664857039","media":"港股解码","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664857039?lang=zh_cn&edition=full","pubTime":"2026-09-01 16:36","pubTimestamp":1788251760,"startTime":"0","endTime":"0","summary":"很多小白投资医药股的痛点：看不懂估值、不知道股价贵不贵、分不清公司前景好坏，上涨就追、下跌就慌，全程凭感觉交易。生物医药的估值体系和普通行业完全不同，成熟药企和创新Biotech更是两套定价逻辑。本篇结合港股成熟药企、Biotech真实估值案例，落地五维打分体系，让小白精准判断港股个股高低估值、长期前景。财报净利润可以通过资产处置、政府补贴、财务调节等方式修饰美化，存在极大水分，但经营性现金流造假难度相对较高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI2MDAzMTQ4OA==&mid=2650514051&idx=1&sn=3182cd32b26f4131e02159d1b357b024&chksm=f311fa39d5689f1a2a3e76c5f2dab5afd2bedf635afbf3b86c087abccf17482d6c6a425bd9e5&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK1574","09939","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664783493","title":"前海开源中药股票8月份跌超5% 医药行情拖累8年老将","url":"https://stock-news.laohu8.com/highlight/detail?id=2664783493","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664783493?lang=zh_cn&edition=full","pubTime":"2026-09-01 16:15","pubTimestamp":1788250503,"startTime":"0","endTime":"0","summary":"中国经济网北京9月1日讯 在刚过去的8月份，受医药行情拖累，前海开源中药股票A/C单月分别下跌5.45%、5.47%。　　前海开源中药股票A/C成立于2018年3月21日，截至2026年8月31日，其成立以来收益率为84.24%、80.90%，累计净值为1.8424元、1.8090元。2018年2月起任前海开源医疗健康灵活配置混合型证券投资基金基金经理。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/01/20260901310528.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/01/20260901310528.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260901/32356438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1515","BK1161","09939","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664884462","title":"恒瑞医药HER2 ADC三期数据积极，国产ADC一线治疗竞争力提升｜医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2664884462","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664884462?lang=zh_cn&edition=full","pubTime":"2026-09-01 09:23","pubTimestamp":1788225791,"startTime":"0","endTime":"0","summary":"截至8月31日收盘，三大指数集体收涨，医药板块集体调整。医药ETF（512120）跟踪指数下跌1.46%，生物医药ETF（159508）跟踪指数下跌1.4%，港股通生物科技ETF（159102）跟踪指数下跌3.61%。相关个股中，泰格医药上涨5.9%，云南白药上涨0.78%，沃森生物下跌4.83%，长春高新下跌3.58%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013860997079.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013860997079.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","159938","01276","LU1997245094.SGD","LU0405327148.USD","LU2097828557.USD","LU1781817850.SGD","LU1997245177.USD","LU2488822045.USD","BK0060","LU2097828474.EUR","BK0183","BK1191","LU1255011170.USD","BK1574","LU2097828631.EUR","LU1969619763.USD","LU2097828805.USD","LU1328615791.USD","LU0405327494.USD","BK0188","LU2543165471.USD","LU1064131003.USD","BK0012","600276","LU2580892862.HKD","LU2289578879.USD","LU1146622755.USD","LU2495084118.USD","LU1023057109.AUD","LU1997244956.HKD","LU2097828714.EUR","BK1161","LU1655091616.SGD","LU1820825898.SGD","BK0239","BK0196","LU0359202008.SGD","BK1515","LU1064130708.USD","09939","LU0359201612.USD","LU2148510915.USD","LU0359201885.HKD","LU2328871848.SGD","LU1580142542.USD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881161","title":"迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881161","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664881161?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:44","pubTimestamp":1788223497,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司于2026年7月14日与AstraZeneca UK Limited(以下简称“阿斯利康”)签署《许可协议》，授予阿斯利康在全球范围内独家开发、商业化舒沃哲®的权利。协议约定的协议生效条件已全部满足，协议于2026年8月31日正式生效。阿斯利康将于今年第四季度在美国实现舒沃哲®商业化。公司将获得阿斯利康支付的一次性、不可返还的首付款6亿美元，最高达4 亿美元的临床开发里程碑款项以及最高达5亿美元的销售里程碑款项，此外公司将获得按舒沃哲®全球销售额最高到低双位数的阶梯式比例的特许权使用费。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09939","BK1574","688192","BK1515","159938","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664886895","title":"新股消息 | 普莱医药二次递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2664886895","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664886895?lang=zh_cn&edition=full","pubTime":"2026-09-01 06:34","pubTimestamp":1788215697,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","09939","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":0.1235},{"period":"1month","weight":0.0964},{"period":"3month","weight":-0.272},{"period":"6month","weight":-0.3746},{"period":"1year","weight":-0.1765},{"period":"ytd","weight":-0.0714}],"compareEarnings":[{"period":"1week","weight":0.0026},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0276},{"period":"6month","weight":-0.0041},{"period":"1year","weight":0.0236},{"period":"ytd","weight":0.0008}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.020286},{"month":2,"riseRate":0.666667,"avgChangeRate":0.174983},{"month":3,"riseRate":0.333333,"avgChangeRate":0.058562},{"month":4,"riseRate":0.666667,"avgChangeRate":0.374359},{"month":5,"riseRate":0.5,"avgChangeRate":0.006013},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.081543},{"month":7,"riseRate":0.571429,"avgChangeRate":0.098094},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.060443},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.10141},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.185801}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}